Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: Concerns.
作者信息
Daungsupawong Hinpetch, Wiwanitkit Viroj
机构信息
Private Academic Consultant, Phonhong, Lao People's Democratic Republic, Laos.
University Centre for Research & Development Department of Pharmaceutical Sciences, Chandigarh University, Mohali, Punjab, India.
出版信息
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1111. doi: 10.31557/APJCP.2024.25.4.1111.
Abstract
摘要
相似文献
1
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: Concerns.严重急性呼吸综合征冠状病毒2型疫苗剂量在异基因造血干细胞接受者中的疗效：关注点。
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1111. doi: 10.31557/APJCP.2024.25.4.1111.
2
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.异基因造血干细胞移植受者接种第三剂BNT162b2后的抗体反应。
Lancet Haematol. 2021 Oct;8(10):e681-e683. doi: 10.1016/S2352-3026(21)00274-X. Epub 2021 Sep 3.
3
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.异基因造血干细胞受者中 SARS-CoV-2 疫苗剂量的疗效：系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):393-399. doi: 10.31557/APJCP.2024.25.2.393.
4
Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant.移植前接种疫苗或感染并不会降低接受同种异体干细胞移植后接种疫苗和/或免疫治疗保护的受者的 COVID-19 感染率。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2370970. doi: 10.1080/21645515.2024.2370970. Epub 2024 Jul 8.
5
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.异基因造血干细胞移植后早期接种三剂重组 SARS-CoV-2 疫苗：预测高血清学反应的指标——一项前瞻性、单臂研究。
Front Immunol. 2023 Apr 19;14:1169666. doi: 10.3389/fimmu.2023.1169666. eCollection 2023.
6
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.异基因造血干细胞移植治疗髓系恶性肿瘤的患者对 COVID-19 mRNA 疫苗的特异性免疫反应会受到免疫抑制治疗的影响。
Leuk Res. 2023 Jul;130:107314. doi: 10.1016/j.leukres.2023.107314. Epub 2023 May 16.
7
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.细胞治疗受者中对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗第三和第四剂的免疫反应：系统评价和荟萃分析。
Virol J. 2024 May 3;21(1):103. doi: 10.1186/s12985-024-02375-1.
8
Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.异基因造血干细胞移植受者加强型 SARS-CoV-2 mRNA 疫苗接种的免疫原性和安全性。
Transplant Cell Ther. 2023 Nov;29(11):706.e1-706.e7. doi: 10.1016/j.jtct.2023.08.008. Epub 2023 Aug 13.
9
Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?异体造血干细胞移植受者接种第三剂 SARS-CoV-2 疫苗有效吗？
Br J Haematol. 2023 Apr;201(1):9-10. doi: 10.1111/bjh.18591. Epub 2022 Dec 7.
10
Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.细胞和体液免疫原性针对 SARS-CoV-2 接种或感染与成年异基因造血细胞移植受者的 T 和 B 淋巴细胞记忆表型相关。
Int J Hematol. 2024 Aug;120(2):229-240. doi: 10.1007/s12185-024-03802-3. Epub 2024 Jun 6.
本文引用的文献
1
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.异基因造血干细胞受者中 SARS-CoV-2 疫苗剂量的疗效：系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):393-399. doi: 10.31557/APJCP.2024.25.2.393.
Zotero 插件